<DOC>
	<DOCNO>NCT02932553</DOCNO>
	<brief_summary>The purpose study determine whether BVS ( Bioresorbable Vascular Scaffold ) implantation optimal medical therapy improve outcome patient variant angina moderate coronary artery disease .</brief_summary>
	<brief_title>BVS Implantation Patients With Variant Angina MODerate Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina Pectoris , Variant</mesh_term>
	<criteria>Age 19 Vasospastic angina diagnose provocation test include ergonovine provocation coronary angiography ergonovine echocardiogram Noischemia produce moderate coronary artery disease ( stenosis &gt; 50 % , FFR &gt; 0.8 ) Ischemic coronary lesion Organic heart disease associate myocardial ischemia sudden cardiac death History percutaneous coronary intervention Cerebrovascular diseases peripheral disease NYHA III IV Cardiac pacemaker implantable defibrillator Pregnancy breast feed Life expectancy le 2 year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bioresorbable vascular scaffold</keyword>
	<keyword>variant angina</keyword>
	<keyword>moderate coronary artery disease</keyword>
	<keyword>vasospastic angina</keyword>
</DOC>